Open Access<p>Blood Targets of Adjuvant Drugs Against COVID19</p>
Author(s) -
Pierpaolo Di Micco,
Gianluca Di Micco,
Vincenzo Russo,
Maria Rita Poggiano,
Ciro Salzano,
Marijan Bosevski,
Michele Imparato,
Luca Fontanella,
Andrea Fontanella
Publication year - 2020
Publication title -
journal of blood medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 18
ISSN - 1179-2736
DOI - 10.2147/jbm.s256121
Subject(s) - medicine , adjuvant , pharmacology , proteases , monoclonal antibody , immunology , antibody , enzyme , biology , biochemistry
While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle.